Currently, several studies have shown that PD‐L1 or tumor mutational burden (TMB) status can be applied to evaluate the efficacy and survival of immunotherapy, so it is promising to use these biomarkers to make therapeutic decisions.14, 15 Herein, a meta‐analysis was performed to make a contrast in terms of the efficacy and safety between ICIs in combination with chemotherapy and chemotherapy or ICIs alone in the first‐line treatment of advanced NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.